Aluminaid Announcement on Private Placement

Since late 2014, Aluminaid shareholder Carl Freer completed a transaction that sees his entire holding in Aluminaid allocated to the current Chairman and CEO, Joe Marten. Freer ceases to have any involvement with the company.

Press Release ( - SINGAPORE - Jun 28, 2017 - The conclusion of this transaction reinforces Marten’s commitment to building a world-class wound care company committed to developing and patenting cutting edge technology that can dramatically improve the quality of life of patients.

To date, the company’s product portfolio consists of a revolutionary aluminum based burn dressing, pulverized aluminum burn spray, aluminum infused hydrogel, ointment and a fever patch for children all of which are based on the simple premise of thermal conductivity using aluminum.

All products are patented and are attracting significant from numerous sales channels including military, advanced wound care, emergency response and OTC.

With advanced wound care revenues expected to top USD 19bn in 2024, Marten believes investing and patenting disruptive technologies will generate significant value for shareholders.

The company’s business model focuses on R&D of patented ideas, navigating regulatory and manufacturing hurdles and contracting business development specialists to partner with larger industry players while keeping a low cost base.

Source : Alumnaid

You may also like this  


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.